StockData
MoonLake Immunotherapeutics logo

MoonLake Immunotherapeutics (MLTX) stock

MLTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 1/30
$11.25−0.48 (-4.09%)

Close on Nov 17, 2026Market cap $957.45MP/E –Yield –

MoonLake Immunotherapeutics pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

MoonLake Immunotherapeutics's pe ratio was 255.5× on Oct 31, 2022.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2022Oct 31, 2022255.5×–

More MoonLake Immunotherapeutics figures

See a number that looks wrong?